Scientists test Double-Drug attack on tough cancers
NCT ID NCT03065062
Summary
This early-stage study is testing the safety of combining two experimental drugs, palbociclib and gedatolisib, for people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the highest dose of this drug combination that patients can tolerate without severe side effects. Researchers hope this two-drug approach will work better than either drug alone to slow or stop cancer growth in tumors of the lung, pancreas, head & neck, and other sites.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.